Melinta Therapeutics, LLC
$976.6K 4,777 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
US Endoscopy
US Endoscopy reported $971,787.56 across General Payments, Research, and Ownership to 103 physicians and teaching hospitals across 103 transactions.
- $971.8K Above-median payer
- All-tracks total
- 103 Below-median volume
- Transactions
- 103 Below-median reach
- Recipients
- +$158.3K
- General Payments vs PY2023
US Endoscopy reported $971,787.56 across all CMS Open Payments tracks (General + Research + Ownership) to 103 physicians and teaching hospitals in Program Year 2024 - ranking #626 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $971,787.56, averaging $9.4K per recipient.
US Endoscopy's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
16/100
Total payments
F
19/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer us-endoscopy US Endoscopy
$971.8K · #626/1,925 · 0.0% industry · PY2024
- TOT $971.8K
- RANK #626
- SHARE 0.0%
- TXN 103
- RCP 103
- CAT 2
- GEN $971.8K
- ΔGEN +$158.3K
- TOP1 40.8%
- PY 2024
Volume peers
Nearest volume peer: Melinta Therapeutics, LLC ($976.6K)
US Endoscopy sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
US Endoscopy's CMS-reported General Payments increased by $158.3K (+19.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: US ENDOSCOPYPY2023: US ENDOSCOPYPY2024: US ENDOSCOPY. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $813,504.13
- PY2024
- $971,787.56
What the Data Shows for US Endoscopy
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For US Endoscopy that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 2 general-payment categories charted below, "Royalty or License" is the largest at $798.2K across 17 transactions, 82.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, US Endoscopy's largest category was "Royalty or License" at $798.2K - 82.1% of General Payments.
How US Endoscopy divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $798.2K | 17 | 82.1% |
| Consulting Fee | $173.6K | 86 | 17.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $828,661.22 (85.3%) of $971,787.56 in this company's General Payments records across 47 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for US Endoscopy
The five named recipients with the highest reported General Payments from this company
- 1
Bennett Roth
$396,092.15 across 4 reported transactions
- 2
David Carr Locke
$325,165.55 across 4 reported transactions
- 3
David Fleischer
$72,994.52 across 5 reported transactions
- 4
Sonali Sethi
$19,659.00 across 7 reported transactions
- 5
Neil Sharma
$14,750.00 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
US Endoscopy's spend rank (#626 of 1,925, top 33% by spend) and concentration rank (#588 of 1,838, top 32% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- NovApproach Spine, LLC : $88.4K total payments, HHI 2890
- Medyssey USA, Inc : $307.8K total payments, HHI 2888
- Vaporox, Inc. : $51.8K total payments, HHI 2887
- Alafair Biosciences, Inc. : $231.7K total payments, HHI 2862
- Aesculap AG : $815.8K total payments, HHI 2859
- Biocartis US, Inc : $9.2K total payments, HHI 2857
- US Endoscopy (this company) : $971.8K total payments, HHI 2854
- X4 Pharmaceuticals, Inc. : $80.9K total payments, HHI 2850
- Ultrasight Inc : $162.3K total payments, HHI 2847
- Steris Corporation : $514.3K total payments, HHI 2847
- Richard Wolf Medical Instruments Corp. : $85.7K total payments, HHI 2845
- Analog Devices Inc. : $22.5K total payments, HHI 2816
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as US Endoscopy's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about US Endoscopy.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with US Endoscopy.
Showing 6 of 1,924 companies with CMS-reported payment data.
pharmaand GmbH
$976.9K 57 recipients
Compare payment profiles
InspireMD Ltd
$983.4K 64 recipients
Compare payment profiles
Topcon Healthcare, Inc.
$985.2K 688 recipients
Compare payment profiles
Hikma Pharmaceuticals USA
$953.3K 3,664 recipients
Compare payment profiles
Almirall LLC
$946.1K 5,128 recipients
Compare payment profiles
Put this to use
US Endoscopy ranks #626 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where US Endoscopy sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just US Endoscopy. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.